SanBio recorded research and development expenses of 680 million yen in the first quarter of the fiscal year ending January 2027, with an operating loss of 953 million yen and a net loss of 836 million yen. The company is advancing approvals for Aducor\u00ae and global expansion efforts.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4592","jir_company_name":"SanBio Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-15","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4592-20260615-01.pdf","jir_short_summary":"SanBio recorded research and development expenses of 680 million yen in the first quarter of the fiscal year ending January 2027, with an operating loss of 953 million yen and a net loss of 836 million yen. The company is advancing approvals for Aducor\u00ae and global expansion efforts.","jir_summary":"### Performance Overview\nIn the first quarter of the fiscal year ending January 2027, SanBio recorded research and development expenses of 680 million yen, an operating loss of 953 million yen, and a net loss of 836 million yen. The main factors include costs related to the approvals and conditional changes for Aducor\u00ae. Foreign exchange gains of 177 million yen reduced the ordinary loss to 779 million yen. The company is progressing with global expansion and clinical trial preparations, and expectations for future growth are high.\n\n### Financial Condition and Outlook\nTotal assets stand at 14,517 million yen, and net assets are 12,677 million yen, reflecting a decrease of 926 million yen from the previous period end. While current assets decreased, fixed assets increased. Liabilities rose to 2,016 million yen, and the equity ratio is 85.5%. Based on ongoing global expansion and clinical trials, the company anticipates medium- to long-term growth.","jir_financial_highlights":"Net loss attributable to owners of the parent in the quarter: 836 million yen (Loss of 1,531 million yen in the same quarter last year)\nResearch and Development expenses: 680 million yen (Compared to the previous period, unknown)\nSales: Unknown (Unknown)","jir_category":"","jir_hashtags":"#SanBio, #FinancialResults, #JapanStocks","jir_key_figures":"Net assets: 12,677 million yen (decreased by 926 million yen from the previous period end)\nNet loss attributable to owners of the parent: 836 million yen\nResearch and Development expenses: 680 million yen","jir_meta_title":"\u3010SanBio\u3011Regenerative Medicine Drug Approval and Research & Development Progress\uff5cJune 2026","jir_meta_description":"SanBio recorded research and development expenses of 680 million yen in the first quarter of the fiscal year ending January 2027, and is advancing approvals for Aducor\u00ae and global expansion efforts. Detailed financial results are explained.","jir_og_title":"\u3010SanBio\u3011Regenerative Medicine Drug Approval and Research & Development Progress\uff5cJune 2026","jir_og_description":"A detailed overview of SanBio\u2019s June 2026 financial results and future prospects. Focus on global expansion and clinical trial progress.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9416,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-64524","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n